V. Bernard

发表

CLINICAL TRIALS STUDY Genomic landscape of pancreatic neuroendocrine tumors

G. Brabant, N. Gebauer, C. Schmidt-Werthern, 2014 .

Comparative analysis of international prognostic indices in gray-zone lymphoma

N. Gebauer, A. Feller, H. Bernd, 2021, Leukemia & lymphoma.

Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.

N. Gebauer, A. Feller, H. Merz, 2014, International journal of clinical and experimental pathology.

Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm

N. Gebauer, A. Feller, H. Merz, 2022, medRxiv.

Integrative genomic and transcriptomic analysis in PBL identifies disruption of key regulatory pathways

N. Gebauer, A. Feller, H. Bernd, 2021 .

Prevalence of targetable oncogenic mutations and genomic alterations in Epstein–Barr virus-associated diffuse large B-cell lymphoma of the elderly

N. Gebauer, A. Feller, D. Rades, 2015, Leukemia & lymphoma.

MicroRNA Expression and JAK2 Allele Burden in Bone Marrow Trephine Biopsies of Polycythemia Vera, Essential Thrombocythemia and Early Primary Myelofibrosis

N. Gebauer, A. Feller, H. Merz, 2013, Acta Haematologica.

The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma

N. Gebauer, D. Rades, H. Lehnert, 2019, British journal of haematology.

Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support

N. Gebauer, D. Rades, H. Lehnert, 2016, Leukemia & lymphoma.

High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

N. Gebauer, A. Feller, H. Merz, 2020, Definitions.

Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective

N. Gebauer, D. Rades, H. Lehnert, 2016, Leukemia & lymphoma.

Deregulation of a distinct set of microRNAs is associated with transformation of gastritis into MALT lymphoma

Silke Szymczak, Andrea Senft, Heinz-Wolfram Bernd, 2012, Virchows Archiv.

Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing

H. Busch, N. Gebauer, A. Feller, 2021, medRxiv.

MicroRNA Profiling of Low-Grade and Transformed Nodal Marginal Zone Lymphoma Reveals a Similar Signature Pattern Distinct from Diffuse Large B Cell Lymphoma

N. Gebauer, A. Feller, C. Thorns, 2014, Acta Haematologica.

MicroRNA-150 Is up-regulated in extranodal marginal zone lymphoma of MALT type.

N. Gebauer, C. Thorns, A. Schillert, 2014, Cancer genomics & proteomics.

TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations

N. Gebauer, A. Feller, C. Thorns, 2015, Leukemia & lymphoma.

ID3 mutations are recurrent events in double-hit B-cell lymphomas.

N. Gebauer, A. Feller, H. Merz, 2013, Anticancer research.

ID 3 Mutations Are Recurrent Events in Double-hit B-Cell Lymphomas

N. Gebauer, A. Feller, H. Merz, 2013 .

Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein‐Barr‐Virus positive diffuse large B cell lymphoma

N. Gebauer, A. Feller, H. Lehnert, 2020, British journal of haematology.

Genomic landscape of pancreatic neuroendocrine tumors.

G. Brabant, N. Gebauer, C. Schmidt-Werthern, 2014, World journal of gastroenterology.

Genomic insights into the pathogenesis of Epstein–Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing

J. Zimmermann, V. Beneš, T. Rausch, 2021, Blood Cancer Journal.

Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid--a study of 21 cases.

G. Brabant, N. Gebauer, A. Feller, 2015, The Journal of clinical endocrinology and metabolism.

Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways

H. Busch, N. Gebauer, A. Feller, 2021, Blood Advances.

High-grade B-cell lymphoma accompanied with MYC and BCL2 and/or BCL6 rearrangements

H. Busch, N. Gebauer, A. Feller, 2021 .

Indolent lymphoma with composite histology and simultaneous transformation at initial diagnosis exhibit clinical features similar to de novo diffuse large B-cell lymphoma

N. Gebauer, D. Rades, H. Lehnert, 2018, Oncotarget.

The Glasgow Prognostic Score at Diagnosis Is a Predictor of Clinical Outcome in Patients with Multiple Myeloma Undergoing Autologous Haematopoietic Stem Cell Transplantation

N. Gebauer, A. Feller, H. Merz, 2020, Cancers.

Global microRNA profiling of pancreatic neuroendocrine neoplasias.

G. Brabant, C. Schurmann, H. Wallaschofski, 2014, Anticancer research.

Primary refractory plasmablastic lymphoma: A precision oncology approach

N. Gebauer, H. Merz, A. Künstner, 2023, Frontiers in Oncology.

Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients

N. Gebauer, A. Feller, H. Bernd, 2020, Blood Cancer Journal.

Dysregulation of microRNAs in angioimmunoblastic T-cell lymphoma.

N. Gebauer, A. Feller, C. Thorns, 2015, Anticancer research.

Oncogenic MYD88 Mutations Are Rare Events in Double-Hit B-Cell Lymphomas

N. Gebauer, A. Feller, C. Thorns, 2014, Acta Haematologica.

Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions

C. Thorns, H. Bernd, V. Bernard, 2017, Leukemia & lymphoma.

Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation

H. Busch, N. Gebauer, A. Feller, 2021, Journal of Cancer Research and Clinical Oncology.

Exhaustion of tumour‐infiltrating T‐cell receptor repertoire diversity is an age‐dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma

N. Gebauer, A. Feller, H. Lehnert, 2020, British Journal of Haematology.

Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.

N. Gebauer, A. Feller, D. Rades, 2014, Anticancer research.

miRNA Expression Correlated with Morphological Findings in Chronic Myeloid Leukemia Treated with Imatinib Mesylate

N. Gebauer, Veronica Bernard, A. Feller, 2013, Acta Haematologica.

Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients

N. Gebauer, A. Feller, H. Bernd, 2020, Blood Cancer Journal.

Pyrosequencing as a Fast and Reliable Method in Detecting the MYD88 p.L265P Mutation in Decalcified Formalin-Fixed and Paraffin-Embedded Tissues

N. Gebauer, A. Feller, C. Thorns, 2014, Annals of laboratory medicine.

Genome-wide DNA methylation-analysis delineates blastic plasmacytoid dendritic cell neoplasm from related entities and identifies distinct molecular features

R. Siebert, H. Sültmann, N. Gebauer, 2023, medRxiv.

Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid--a study of 21 cases.

G. Brabant, N. Gebauer, A. Feller, 2015, The Journal of clinical endocrinology and metabolism.

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)

N. Gebauer, H. Merz, A. Künstner, 2023, Targeted oncology.

Integrative molecular profiling identifies two molecularly and clinically distinct subtypes of blastic plasmacytoid dendritic cell neoplasm

N. Gebauer, A. Feller, H. Merz, 2022, Blood Cancer Journal.

Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements

N. Gebauer, H. Witte, N. von Bubnoff, 2021, Cancers.

Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective

N. Gebauer, D. Rades, H. Lehnert, 2016, Leukemia & lymphoma.